INKT 8-K: SEC filing
MiNK Therapeutics
Filed with the SEC on · accession 0001193125-26-457244
INKT filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
MiNK Therapeutics announced its financial results for the quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.
Key details
✦ Ask GOAX AI about this filing — what it means for INKT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for INKT?
Click hereFrequently asked questions
What did INKT file with the SEC on Nov 12, 2026?
INKT filed a 8-K (SEC filing). MiNK Therapeutics announced its financial results for the quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other INKT SEC filings
Get alerts when INKT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days